In Brief This Week: Life Technologies, Asuragen; Synthetic Genomics, Exxon Mobil; Immucor; Tecan; Millipore | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Life Technologies today said that it and partner Asuragen have achieved CE marking and launched in Europe their BCR/ABL1 Quant Test, which is used to monitor treatment of chronic myeloid leukemia patients. Asuragen manufactures the test, and Life Technologies exclusively distributes the test, which runs on the Applied Biosystems 7500 Fast Dx Real-Time PCR Instrument.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.